Karyopharm down as FDA reviewers cast doubt on selinexor's benefit

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) lost $3.90 (43%) to $5.07 on Friday after FDA reviewers wrote in briefing documents that it is unclear whether treatment with selinexor provides

Read the full 279 word article

User Sign In